Trial Profile
Efficacy and safety of low-dose sofosbuvir plus full-dose daclatasvir in chronic hepatitis C patients with severe renal impairment or end-stage renal disease: A real-life study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Mar 2018
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 09 Mar 2018 New trial record
- 26 Feb 2018 Results published in the Digestive Diseases and Sciences